379 related articles for article (PubMed ID: 34285106)
1. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
2. Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Ivasko SM; Anders K; Grunewald L; Launspach M; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Lode HN; Andersch L; Schulte JH; Eggert A; Hundsdoerfer P; Künkele A; Zirngibl F
Front Immunol; 2022; 13():1023206. PubMed ID: 36700232
[TBL] [Abstract][Full Text] [Related]
3. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
Ruf P; Schäfer B; Eissler N; Mocikat R; Hess J; Plöscher M; Wosch S; Suckstorff I; Zehetmeier C; Lindhofer H
J Transl Med; 2012 Nov; 10():219. PubMed ID: 23134699
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery.
Deppisch N; Ruf P; Eissler N; Neff F; Buhmann R; Lindhofer H; Mocikat R
Mol Cancer Ther; 2015 Aug; 14(8):1877-83. PubMed ID: 26063765
[TBL] [Abstract][Full Text] [Related]
5. Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3).
Arendt AM; Heubach F; Maier CP; Giardino S; Jung G; Kowalewski E; Rabsteyn A; Amorelli G; Seitz C; Schlegel P; Handgretinger R; Lang P
Cancer Immunol Immunother; 2023 Nov; 72(11):3813-3824. PubMed ID: 37742286
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
7. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
8. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Mora J
Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
[TBL] [Abstract][Full Text] [Related]
9. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
10. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
12. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
13. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
[TBL] [Abstract][Full Text] [Related]
14. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
15. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
Cheng M; Ahmed M; Xu H; Cheung NK
Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
[TBL] [Abstract][Full Text] [Related]
18. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
19. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
20. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]